Key Points
-
Adenosine, generated from the extracellular hydrolysis of ATP, is a potent endogenous regulator of inflammation and immune reactions via interaction with one or more cell surface receptors
-
The principal adenosine receptor involved in regulation of adaptive T cell responses is A2a
-
A2a, A2b and A3 downregulate macrophage-mediated inflammatory actions, although A2b might indirectly stimulate type 17 T helper cell immune responses via increased IL-6 production
-
Adenosine mediates the anti-inflammatory effects of low-dose methotrexate treatment as well as some of the anti-inflammatory effects of sulfasalazine
Abstract
Adenosine, a nucleoside derived primarily from the extracellular hydrolysis of adenine nucleotides, is a potent regulator of inflammation. Adenosine mediates its effects on inflammatory cells by engaging one or more cell-surface receptors. The expression and function of adenosine receptors on different cell types change during the course of rheumatic diseases, such as rheumatoid arthritis (RA). Targeting adenosine receptors directly for the treatment of rheumatic diseases is currently under study; however, indirect targeting of adenosine receptors by enhancing adenosine levels at inflamed sites accounts for most of the anti-inflammatory effects of methotrexate, the anchor drug for the treatment of RA. In this Review, we discuss the regulation of extracellular adenosine levels and the role of adenosine in regulating the inflammatory and immune responses in rheumatic diseases such as RA, psoriasis and other types of inflammatory arthritis. In addition, adenosine and its receptors are involved in promoting fibrous matrix production in the skin and other organs, and the role of adenosine in fibrosis and fibrosing diseases is also discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrrheum.2016.178/MediaObjects/41584_2017_Article_BFnrrheum2016178_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrrheum.2016.178/MediaObjects/41584_2017_Article_BFnrrheum2016178_Fig2_HTML.jpg)
Similar content being viewed by others
References
Drury, A. N. & Szent-Gyorgi, A. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. 68, 213–237 (1929).
Sattin, A. & Rall, T. W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 6, 13–23 (1970).
Fredholm, B. B. et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors — an update. Pharmacol. Rev. 63, 1–34 (2011).
Newby, A. C., Holmquist, C. A., Illingworth, J. & Pearson, J. D. The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem. J. 214, 317–323 (1983).
Beyer, E. C. & Steinberg, T. H. Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages. J. Biol. Chem. 266, 7971–7974 (1991).
Rosenthal, A. K. et al. The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes. Arthritis Res. Ther. 15, R154 (2013).
Bao, L., Locovei, S. & Dahl, G. Pannexin membrane channels are mechanosensitive conduits for ATP. FEBS Lett. 572, 65–68 (2004).
Iglesias, R. et al. P2X7 receptor–Pannexin1 complex: pharmacology and signaling. Am. J. Physiol. Cell Physiol. 295, C752–C760 (2008).
Baldwin, S. A. et al. The equilibrative nucleoside transporter family, SLC29. Pflügers Arch. 447, 735–743 (2004).
Dahl, G. & Muller, K. J. Innexin and pannexin channels and their signaling. FEBS Lett. 588, 1396–1402 (2014).
Adamson, S. E. & Leitinger, N. The role of pannexin1 in the induction and resolution of inflammation. FEBS Lett. 588, 1416–1422 (2014).
Alberto, A. V. et al. Is pannexin the pore associated with the P2X7 receptor? Naunyn Schmiedebergs Arch. Pharmacol. 386, 775–787 (2013).
Ambrosi, C. et al. Pannexin1 and Pannexin2 channels show quaternary similarities to connexons and different oligomerization numbers from each other. J. Biol. Chem. 285, 24420–24431 (2010).
Anselmi, F. et al. ATP release through connexin hemichannels and gap junction transfer of second messengers propagate Ca2+ signals across the inner ear. Proc. Natl Acad. Sci. USA 105, 18770–18775 (2008).
Beckel, J. M. et al. Mechanosensitive release of adenosine 5′-triphosphate through pannexin channels and mechanosensitive upregulation of pannexin channels in optic nerve head astrocytes: a mechanism for purinergic involvement in chronic strain. Glia 62, 1486–1501 (2014).
Iwamoto, T. et al. Pannexin 3 regulates intracellular ATP/cAMP levels and promotes chondrocyte differentiation. J. Biol. Chem. 285, 18948–18958 (2010).
Levick, J. R. Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. J. Rheumatol. 17, 579–582 (1990).
Geborek, P., Forslind, K. & Wollheim, F. A. Direct assessment of synovial blood flow and its relation to induced hydrostatic pressure changes. Ann. Rheum. Dis. 48, 281–286 (1989).
Kofoed, H. Synovitis causes hypoxia and acidity in synovial fluid and subchondral bone. Injury 17, 391–394 (1986).
Grenz, A., Homann, D. & Eltzschig, H. K. Extracellular adenosine: a safety signal that dampens hypoxia-induced inflammation during ischemia. Antioxid. Redox Signal. 15, 2221–2234 (2011).
Fearon, U., Canavan, M., Biniecka, M. & Veale, D. J. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 385–397 (2016).
Borea, P. A. et al. The A3 adenosine receptor: history and perspectives. Pharmacol. Rev. 67, 74–102 (2015).
Fredholm, B. B. et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527–552 (2001).
Khoa, N. D., Montesinos, C. M., Williams, A. J., Kelly, M. & Cronstein, B. N. Th1 cytokines regulate adenosine receptors and their downstream signalling elements in human microvascular endothelial cells. J. Immunol. 171, 3991–3998 (2003).
Khoa, N. D. et al. Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytic THP-1 cells. J. Immunol. 167, 4026–4032 (2001).
Bshesh, K. et al. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J. Leukoc. Biol. 72, 1027–1036 (2002).
Sun, W. C. et al. Lipopolysaccharide and TNF-α modify adenosine A2A receptor expression and function in equine monocytes. Vet. Immunol. Immunopathol. 135, 289–295 (2010).
Napieralski, R., Kempkes, B. & Gutensohn, W. Evidence for coordinated induction and repression of ecto-5′-nucleotidase (CD73) and the A2a adenosine receptor in a human B cell line. Biol. Chem. 384, 483–487 (2003).
Varani, K. et al. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor α but not methotrexate. Arthritis Rheum. 60, 2880–2891 (2009).
Vincenzi, F. et al. A2A adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLoS ONE 8, e54195 (2013).
Khoa, N. D., Postow, M., Danielsson, J. & Cronstein, B. N. Tumor necrosis factor-α prevents desensitization of GαS-coupled receptors by regulating GRK2 association with the plasma membrane. Mol. Pharmacol. 69, 1311–1319 (2006).
Nguyen, D. K., Montesinos, M. C., Williams, A. J., Kelly, M. & Cronstein, B. N. Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. J. Immunol. 171, 3991–3998 (2003).
Block, E. T. & Cronstein, B. N. Interferon-gamma inhibits adenosine A2A receptor function in hepatic stellate cells by STAT1-mediated repression of adenylyl cyclase. Int. J. Interferon Cytokine Mediat. Res. 2010, 113–126 (2010).
Fishman, P. & Cohen, S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin. Rheumatol. 35, 2359–2362 (2016).
Ochaion, A. et al. The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell. Immunol. 258, 115–122 (2009).
Ochaion, A. et al. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res. Ther. 8, R169 (2006).
Cronstein, B. N., Kramer, S. B., Weissmann, G. & Hirschhorn, R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med. 158, 1160–1177 (1983).
Cronstein, B. N., Rosenstein, E. D., Kramer, S. B., Weissmann, G. & Hirschhorn, R. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 135, 1366–1371 (1985).
Marone, G., Petracca, R. & Vigorita, S. Adenosine receptors on human inflammatory cells. Int. Arch. Allergy Appl. Immunol. 77, 259–263 (1985).
Pasini, F. L., Capecchi, P. L., Orrico, A., Ceccatelli, L. & DiPierri, T. Adenosine inhibits polymorphonuclear leukocyte in vitro activation: a possible role as an endogenous calcium entry blocker. J. Immunopharmacol. 7, 203–215 (1985).
Roberts, P. A., Morgan, B. P. & Campbell, A. K. 2-chloroadenosine inhibits complement-induced reactive oxygen metabolite production and recovery of human polymorphonuclear leukocytes attacked by complement. Biochem. Biophys. Res. Commun. 126, 692–697 (1985).
Cronstein, B. N., Daguma, L., Nichols, D., Hutchison, A. J. & Williams, M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J. Clin. Invest. 85, 1150–1157 (1990).
Gurden, M. F. et al. Functional characterization of three adenosine receptor types. Br. J. Pharmacol. 109, 693–698 (1993).
Fredholm, B. B., Zhang, Y. & van der Ploeg, I. Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. Naunyn Schmiedebergs Arch. Pharmacol. 354, 262–267 (1996).
Thiel, M. et al. Effects of adenosine on the functions of circulating polymorphonuclear leukocytes during hyperdynamic endotoxemia. Infect. Immun. 65, 2136–2144 (1997).
Bullough, D. A., Magill, M. J., Mullane, K. M. & Firestein, G. S. Carbohydrate- and CD18-dependent neutrophil adhesion to cardiac myocytes: effects of adenosine. Cardiovasc. Res. 32, 328–334 (1996).
Firestein, G. S. et al. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J. Immunol. 154, 326–334 (1995).
Cronstein, B. N. et al. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148, 2201–2206 (1992).
Cronstein, B. N., Levin, R. I., Belanoff, J., Weissmann, G. & Hirschhorn, R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78, 760–770 (1986).
Rose, F. R., Hirschhorn, R., Weissmann, G. & Cronstein, B. N. Adenosine promotes neutrophil chemotaxis. J. Exp. Med. 167, 1186–1194 (1988).
Inoue, Y., Chen, Y., Hirsh, M. I., Yip, L. & Junger, W. G. A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock 30, 173–177 (2008).
Chen, Y. et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314, 1792–1795 (2006).
Duro, E., Pallai, A., Koroskenyi, K., Sarang, Z. & Szondy, Z. Adenosine A3 receptors negatively regulate the engulfment-dependent apoptotic cell suppression of inflammation. Immunol. Lett. 162, 292–301 (2014).
Koroskenyi, K. et al. Involvement of adenosine A2A receptors in engulfment-dependent apoptotic cell suppression of inflammation. J. Immunol. 186, 7144–7155 (2011).
Smail, E. H. et al. In vitro, Candida albicans releases the immune modulator adenosine and a second, high-molecular weight agent that blocks neutrophil killing. J. Immunol. 148, 3588–3595 (1992).
Thammavongsa, V., Kern, J. W., Missiakas, D. M. & Schneewind, O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J. Exp. Med. 206, 2417–2427 (2009).
Liu, P. et al. Streptococcus suis adenosine synthase functions as an effector in evasion of PMN-mediated innate immunit. J. Infect. Dis. 210, 35–45 (2014).
Sica, A., Erreni, M., Allavena, P. & Porta, C. Macrophage polarization in pathology. Cell. Mol. Life Sci. 72, 4111–4126 (2015).
Laria, A. et al. The macrophages in rheumatic diseases. J. Inflamm. Res. 9, 1–11 (2016).
Csoka, B. et al. A2A adenosine receptors and C/EBPβ are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 110, 2685–2695 (2007).
Ferrante, C. J. et al. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling. Inflammation 36, 921–931 (2013).
Grinberg, S., Hasko, G., Wu, D. & Leibovich, S. J. Suppression of PLCβ2 by endotoxin plays a role in the adenosine A2A receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am. J. Pathol. 175, 2439–2453 (2009).
Hasko, G. et al. Adenosine inhibits IL-12 and TNF-α production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14, 2065–2074 (2000).
Hasko, G. et al. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157, 4634–4640 (1996).
Nemeth, Z. H. et al. Adenosine stimulates CREB activation in macrophages via a p38 MAPK-mediated mechanism. Biochem. Biophys. Res. Commun. 312, 883–888 (2003).
Nemeth, Z. H. et al. Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J. Immunol. 175, 8260–8270 (2005).
Pinhal-Enfield, G. et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A2A receptors. Am. J. Pathol. 163, 711–721 (2003).
Ramanathan, M. et al. Differential regulation of HIF-1α isoforms in murine macrophages by TLR4 and adenosine A2A receptor agonists. J. Leukoc. Biol. 86, 681–689 (2009).
Szabo, C. et al. Suppression of macrophage inflammatory protein (MIP)-1αproduction and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125, 379–387 (1998).
Leibovich, S. et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A2A receptor agonists and endotoxin. Am. J. Path. 160, 2231–2244 (2002).
Williams, A. J. & Cronstein, B. N. The effect of A2A adenosine receptor activation on C-C chemokine receptor 7 expression in human THP1 macrophages during inflammation. Inflammation 35, 614–622 (2011).
Crean, D. et al. Adenosine modulates NR4A orphan nuclear receptors to attenuate hyperinflammatory responses in monocytic cells. J. Immunol. 195, 1436–1448 (2015).
Murphy, E. P. & Crean, D. Molecular interactions between NR4A orphan nuclear receptors and NF-κB are required for appropriate inflammatory responses and immune cell homeostasis. Biomolecules 5, 1302–1318 (2015).
Tian, Y., Piras, B. A., Kron, I. L., French, B. A. & Yang, Z. Adenosine 2B receptor activation reduces myocardial reperfusion injury by promoting anti-inflammatory macrophages differentiation via PI3K/Akt pathway. Oxid. Med. Cell. Longev. 2015, 585297 (2015).
Sciaraffia, E. et al. Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors. J. Leukoc. Biol. 96, 113–122 (2014).
Koscso, B. et al. Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. J. Leukoc. Biol. 94, 1309–1315 (2013).
Lee, H. S., Chung, H. J., Lee, H. W., Jeong, L. S. & Lee, S. K. Suppression of inflammation response by a novel A3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling. Immunobiology 216, 997–1003 (2011).
Ramakers, B. P. et al. The effect of adenosine receptor agonists on cytokine release by human mononuclear cells depends on the specific Toll-like receptor subtype used for stimulation. Cytokine 35, 95–99 (2006).
Levy, O. et al. The adenosine system selectively inhibits TLR-mediated TNF-α production in the human newborn. J. Immunol. 177, 1956–1966 (2006).
Mabley, J. et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. 466, 323–329 (2003).
Knight, D. et al. Adenosine A3 receptor stimulation inhibits migration of human eosinophils. J. Leukoc. Biol. 62, 465–468 (1997).
Bowlin, T. L., Borcherding, D. R., Edwards, C. K. 3rd & McWhinney, C. D. Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell. Mol. Biol. (Noisy-le-Grand) 43, 345–349 (1997).
McWhinney, C. D. et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-α. Eur. J. Pharmacol. 310, 209–216 (1996).
Sajjadi, F. G., Takabayashi, K., Foster, A. C., Domingo, R. C. & Firestein, G. S. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156, 3435–3442 (1996).
Hasko, G., Csoka, B., Nemeth, Z. H., Vizi, E. S. & Pacher, P. A2B adenosine receptors in immunity and inflammation. Trends Immunol. 30, 263–270 (2009).
Wilson, J. M. et al. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. J. Immunol. 186, 6746–6752 (2011).
Liang, D. et al. A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c+Gr-1+ dendritic cell subset that promotes the Th17 response. Immun. Inflamm. Dis. 3, 360–373 (2015).
Teramachi, J. et al. Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. Lab. Invest. 91, 719–731 (2011).
Merrill, J. T. et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 40, 1308–1315 (1997).
Kara, F. M. et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J. 24, 2325–2333 (2010).
He, W. & Cronstein, B. N. Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling. Purinergic Signal. 8, 327–337 (2012).
He, W., Mazumder, A., Wilder, T. & Cronstein, B. N. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 27, 3446–3454 (2013).
Mediero, A., Kara, F. M., Wilder, T. & Cronstein, B. N. Adenosine A2A receptor ligation inhibits osteoclast formation. Am. J. Pathol. 180, 775–786 (2012).
Corciulo, C., Wilder, T. & Cronstein, B. N. Adenosine A2B receptors play an important role in bone homeostasis. Purinergic Signal. 12, 537–547 (2016).
Mediero, A., Frenkel, S., Wilder, T. & Cronstein, B. N. Activation of adenosine A2A receptors prevents wear particle-induced osteolysis [abstract]. Arthritis Rheum. 63 (Suppl. 10), 1781 (2011).
Mediero, A., Wilder, T., Perez-Aso, M. & Cronstein, B. N. Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2. FASEB J. 29, 1577–1590 (2015).
Carroll, S. H. et al. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J. Biol. Chem. 287, 15718–15727 (2012).
Strazzulla, L. C. & Cronstein, B. N. Regulation of bone and cartilage by adenosine signaling. Purinergic Signal. http://dx.doi.org/10.1007/s11302-016-9527-2 (2016).
Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).
Ohta, A. et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA 103, 13132–13137 (2006).
Huang, S., Apasov, S., Koshiba, M. & Sitkovsky, M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90, 1600–1610 (1997).
Koshiba, M., Kojima, H., Huang, S., Apasov, S. & Sitkovsky, M. V. Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272, 25881–25889 (1997).
Lappas, C. M., Rieger, J. M. & Linden, J. A2A adenosine receptor induction inhibits IFN-γ production in murine CD4+ T cells. J. Immunol. 174, 1073–1080 (2005).
Lukashev, D., Ohta, A., Apasov, S., Chen, J. F. & Sitkovsky, M. Cutting edge: physiologic attenuation of proinflammatory transcription by the GS protein-coupled A2A adenosine receptor in vivo. J. Immunol. 173, 21–24 (2004).
Armstrong, J. M. et al. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem. J. 354, 123–130 (2001).
Hillger, J. M. et al. Getting personal: endogenous adenosine receptor signaling in lymphoblastoid cell lines. Biochem. Pharmacol. 115, 114–122 (2016).
Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J. & Sitkovsky, M. V. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol. Pharmacol. 55, 614–624 (1999).
Csoka, B. et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 22, 3491–3499 (2008).
Alam, M. S. et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol. 2, 232–242 (2009).
Himer, L. et al. Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. FASEB J. 24, 2631–2640 (2010).
Cekic, C., Sag, D., Day, Y. J. & Linden, J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. J. Exp. Med. 210, 2693–2706 (2013).
Apasov, S., Chen, J. F., Smith, P. & Sitkovsky, M. A2A receptor dependent and A2A receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood 95, 3859–3867 (2000).
Takayama, H., Trenn, G. & Sitkovsky, M. V. Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J. Biol. Chem. 263, 2330–2336 (1988).
Sitkovsky, M. V., Trenn, G. & Takayama, H. Cyclic AMP-dependent protein kinase as a part of the possible down-regulating pathway in the antigen receptor-regulated cytotoxic T lymphocyte conjugate formation and granule exocytosis. Ann. NY Acad. Sci. 532, 350–358 (1988).
Sitkovsky, M. V. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol. 30, 102–108 (2009).
Hatfield, S., Belikoff, B., Lukashev, D., Sitkovsky, M. & Ohta, A. The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. J. Leukoc. Biol. 86, 545–548 (2009).
Chen, M. et al. An A2B adenosine receptor agonist promotes Th17 autoimmune responses in experimental autoimmune uveitis (EAU) via dendritic cell activation. PLoS ONE 10, e0132348 (2015).
Ehrentraut, H., Westrich, J. A., Eltzschig, H. K. & Clambey, E. T. Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation. PLoS ONE 7, e32416 (2012).
Cohen, M. V., Yang, X. & Downey, J. M. A2b adenosine receptors can change their spots. Br. J. Pharmacol. 159, 1595–1597 (2010).
Gessi, S. et al. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br. J. Pharmacol. 134, 116–126 (2001).
Feoktistov, I., Biaggioni, I. & Cronstein, B. N. Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb. Exp. Pharmacol. 193, 383–397 (2009).
Montesinos, M. C. et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. Am. J. Pathol. 160, 2009–2018 (2002).
Hassanian, S. M., Dinarvand, P. & Rezaie, A. R. Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells. J. Cell. Physiol. 229, 1292–1300 (2014).
Eckle, T., Grenz, A., Laucher, S. & Eltzschig, H. K. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J. Clin. Invest. 118, 3301–3315 (2008).
Shaikh, G. & Cronstein, B. Signaling pathways involving adenosine A2A and A2B receptors in wound healing and fibrosis. Purinergic Signal. 12, 191–197 (2016).
Cronstein, B. N. Adenosine receptors and fibrosis: a translational review. F1000 Biol. Rep. 3, 21 (2011).
Chan, E. S. et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 54, 2632–2642 (2006).
Fernandez, P. et al. Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am. J. Pathol. 172, 1675–1682 (2008).
Katebi, M., Fernandez, P., Chan, E. S. & Cronstein, B. N. Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. Inflammation 31, 299–303 (2008).
Perez-Aso, M., Chiriboga, L. & Cronstein, B. N. Pharmacological blockade of adenosine A2A receptors diminishes scarring. FASEB J. 26, 4254–4263 (2012).
Blackburn, M. R. et al. Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J. Clin. Invest. 112, 332–344 (2003).
Chunn, J. L. et al. Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L579–L587 (2006).
Chunn, J. L. et al. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J. Immunol. 175, 1937–1946 (2005).
Ma, B. et al. Adenosine metabolism and murine strain-specific IL-4-induced inflammation, emphysema, and fibrosis. J. Clin. Invest. 116, 1274–1283 (2006).
Schneider, D. J., Lindsay, J. C., Zhou, Y., Molina, J. G. & Blackburn, M. R. Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease. FASEB J. 24, 70–80 (2010).
Sun, C. X. et al. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. 116, 2173–2182 (2006).
Zhou, Y., Murthy, J. N., Zeng, D., Belardinelli, L. & Blackburn, M. R. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS ONE 5, e9224 (2010).
Zhou, Y. et al. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 186, 1097–1106 (2011).
Chan, E. S. et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148, 1144–1155 (2006).
Peng, Z. et al. Ecto-5′-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J. 22, 2263–2272 (2008).
Robson, S. C. & Schuppan, D. Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J. Hepatol. 52, 941–943 (2010).
Corrao, G. et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case–control study. Provincial group for the study of chronic liver disease. Eur. J. Epidemiol. 10, 657–664 (1994).
Corrao, G., Zambon, A., Bagnardi, V., D'Amicis, A. & Klatsky, A. Coffee, caffeine, and the risk of liver cirrhosis. Ann. Epidemiol. 11, 458–465 (2001).
Klatsky, A. L. & Armstrong, M. A. Alcohol, smoking, coffee, and cirrhosis. Am. J. Epidemiol. 136, 1248–1257 (1992).
Tverdal, A. & Skurtveit, S. Coffee intake and mortality from liver cirrhosis. Ann. Epidemiol. 13, 419–423 (2003).
Ferrari, D. et al. Purinergic signaling in scarring. FASEB J. 30, 3–12 (2016).
Nakav, S. et al. Blocking adenosine A2A receptor reduces peritoneal fibrosis in two independent experimental models. Nephrol. Dial. Transplant. 24, 2392–2399 (2009).
Mi, T. et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J. Clin. Invest. 118, 1491–1501 (2008).
Wen, J. et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 24, 740–749 (2010).
Berne, R. M. & Belardinelli, L. Effects of hypoxia and ischaemia on coronary vascular resistance, A-V node conduction and S-A node excitation. Acta Med. Scand. Suppl. 694, 9–19 (1985).
Morote-Garcia, J. C., Rosenberger, P., Kuhlicke, J. & Eltzschig, H. K. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 111, 5571–5580 (2008).
Waidmann, O. et al. Inhibition of the equilibrative nucleoside transporter 1 and activation of A2A adenosine receptors by 8-(4-chlorophenylthio)-modified cAMP analogs and their hydrolytic products. J. Biol. Chem. 284, 32256–32263 (2009).
Nagy, L. E., Diamond, I., Casso, D. J., Franklin, C. & Gordon, A. S. Ethanol increases extracellular adenosine by inhibiting adenosine uptake via the nucleoside transporter. J. Biol. Chem. 265, 1946–1951 (1990).
Rothschild, B. M. & Masi, A. T. Pathogenesis of rheumatoid arthritis: a vascular hypothesis. Semin. Arthritis Rheum. 12, 11–31 (1982).
Richman, A. I., Su, E. Y. & Ho, G. Jr. Reciprocal relationship of synovial fluid volume and oxygen tension. Arthritis Rheum. 24, 701–705 (1981).
Zamani, B., Jamali, R. & Ehteram, H. Synovial fluid adenosine deaminase and high-sensitivity C-reactive protein activity in differentiating monoarthritis. Rheumatol. Int. 32, 183–188 (2012).
Huang, L. F., Guo, F. Q., Liang, Y. Z., Li, B. Y. & Cheng, B. M. Simple and rapid determination of adenosine in human synovial fluid with high performance liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 36, 877–882 (2004).
Ottonello, L. et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology 41, 1249–1260 (2002).
Cattaneo, M., Schulz, R. & Nylander, S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J. Am. Coll. Cardiol. 63, 2503–2509 (2014).
Armstrong, D. et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J. Cardiovasc. Pharmacol. Ther. 19, 209–219 (2014).
Nagy, L. E. et al. Adenosine is required for ethanol-induced heterologous desensitization. Mol. Pharmacol. 36, 744–748 (1989).
Gordon, A. S., Nagy, L., Mochly-Rosen, D. & Diamond, I. Chronic ethanol-induced heterologous desensitization is mediated by changes in adenosine transport. Biochem. Soc. Symp. 56, 117–136 (1990).
Diamond, I., Nagy, L., Mochly-Rosen, D. & Gordon, A. The role of adenosine and adenosine transport in ethanol-induced cellular tolerance and dependence. Possible biologic and genetic markers of alcoholism. Ann. NY Acad. Sci. 625, 473–487 (1991).
Peng, Z. et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J. Clin. Invest. 119, 582–594 (2009).
Chouker, A. et al. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol. Med. 14, 116–123 (2008).
Chan, E. S. & Cronstein, B. N. Methotrexate — how does it really work? Nat. Rev. Rheumatol. 6, 175–178 (2010).
Cronstein, B. N., Eberle, M. A., Gruber, H. E. & Levin, R. I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl Acad. Sci. USA 88, 2441–2445 (1991).
Cronstein, B. N., Naime, D. & Ostad, E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675–2682 (1993).
Montesinos, C. et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43, 656–663 (2000).
Nesher, G., Mates, M. & Zevin, S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 48, 571–572 (2003).
Silke, C. et al. The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology 40 (Suppl 1), 34 (2001).
Benito-Garcia, E. et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J. Rheumatol. 33, 1275–1281 (2006).
Peres, R. S. et al. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 112, 2509–2514 (2015).
Olsen, N. J., Spurlock, C. F. III & Aune, T. M. Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res. Ther. 16, R17 (2014).
Spurlock, C. F. III, Tossberg, J. T., Fuchs, H. A., Olsen, N. J. & Aune, T. M. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 64, 1780–1789 (2012).
Spurlock, C. F. III et al. Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes. Rheumatology 54, 178–187 (2015).
Lindenbaum, J. Drugs and vitamin B12 and folate metabolism. Curr. Concepts Nutr. 12, 73–87 (1983).
Gadangi, P. et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156, 1937–1941 (1996).
Morabito, L. et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101, 295–300 (1998).
Mehlman, M. A., Tobin, R. B., Madappally, M. M. & Hahn, H. K. Mode of action of aspirin. Effect of dietary aspirin on mitochondrial pyruvate metabolism in normal and thiamine-deficient rats. J. Biol. Chem. 246, 1618–1622 (1971).
Thompkins, L. & Lee, K. H. Studies on the mechanism of action of salicylates. IV. Effect of salicylates on oxidative phosphorylation. J. Pharm. Sci. 58, 102–105 (1969).
Cronstein, B. N., Van de Stouwe, M., Druska, L., Levin, R. I. & Weissmann, G. Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms. Inflammation 18, 323–335 (1994).
Cronstein, B. N., Montesinos, M. C. & Weissmann, G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB. Proc. Natl Acad. Sci. USA 96, 6377–6381 (1999).
Baharav, E. et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32, 469–476 (2005).
Silverman, M. H. et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J. Rheumatol. 35, 41–48 (2008).
David, M. et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J. Eur. Acad. Dermatol. Venereol. 26, 361–367 (2012).
Gubner, R., August, S. & Ginsberg, V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 221, 176–182 (1951).
Weinblatt, M. E. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans. Am. Clin. Climatol. Assoc. 124, 16–25 (2013).
Morgan, S. L. et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Internal Med. 121, 833–841 (1994).
Morgan, S. L., Baggott, J. E., Koopman, W. J., Krumdieck, C. L. & Alarcon, G. S. Folate supplementation and methotrexate. Ann. Rheum. Dis. 52, 315–316 (1993).
Morgan, S. L. et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 33, 9–18 (1990).
Acknowledgements
The work of B.N.C. is supported by grants from the NIH (R01 AR056672-07, R01 AR068593-02, 1UL1TR001445-02), Arthritis Foundation and Celgene. The work of M.S. is supported by a grant from the NIH (2R01 CA 111985–10).
Author information
Authors and Affiliations
Contributions
Both authors contributed to all aspects of this manuscript.
Corresponding author
Ethics declarations
Competing interests
B.N.C. has acted as a consultant for Bristol–Myers Squibb and AstraZeneca; he has received grants from AstraZeneca, Celgene and Takeda and has equity in Can-Fite Biopharma. M.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Cronstein, B., Sitkovsky, M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol 13, 41–51 (2017). https://doi.org/10.1038/nrrheum.2016.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.178
This article is cited by
-
Effect of adenosine treatment on ionizing radiation toxicity in zebrafish early life stages
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Purinergic receptor: a crucial regulator of adipose tissue functions
Purinergic Signalling (2023)
-
Determination of adenosine by CRISPR-Cas12a system based on duplexed aptamer and molecular beacon reporter linked to gold nanoparticles
Microchimica Acta (2023)
-
Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment
Clinical Rheumatology (2023)
-
In vivo phenotypic validation of adenosine receptor-dependent activity of non-adenosine drugs
Purinergic Signalling (2023)